Thomas Harvey, MD
Ophthalmology · Chippewa Falls, WINPI 1457353435
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.5%), gifts and food and beverage — rather than concentrated in one kind of arrangement. Carl Zeiss Meditec, Inc. accounts for 63.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $7,939 and has fallen 74.6% since, to $2,013 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $176.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$14K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Alcon$1K
- Topcon Healthcare, Inc.$1K
- Lensar, Inc.$722
- AbbVie$670
- plus $2K from 19 others
What the payments were for
- Consulting fees$10,72048%
- Speaking & faculty fees$1,0004%
- Food & beverage$4,36319%
- Gifts$6,46229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 7 | $14,257 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,510 |
| Alcon | 32 | $1,300 |
| Topcon Healthcare, Inc. | 1 | $1,000 |
| Lensar, Inc. | 4 | $722 |
| AbbVie(2 entities) | 25 | $670 |
| NEW World Medical,inc. | 3 | $535 |
| Glaukos Corporation | 6 | $268 |
| Carl Zeiss Meditec USA, Inc. | 1 | $210 |
| Rxsight Inc | 2 | $189 |
| Dompe US, Inc. | 1 | $139 |
| Rayner Intraocular Lenses Limited | 7 | $131 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $102 |
| Carl Zeiss Meditec Cataract Technology Inc. | 4 | $77 |
| The Cameron-ehlen Group, Inc. | 5 | $77 |
| Sun Pharmaceutical Industries Inc. | 5 | $76 |
| Eyepoint US, Inc. | 2 | $58 |
| Bausch & Lomb Americas Inc. | 2 | $42 |
| Ocular Therapeutix, Inc. | 2 | $38 |
| Omeros Corporation | 2 | $37 |
| Align Ophthalmics LLC | 1 | $33 |
| Aerie Pharmaceuticals, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Novartis | 1 | $13 |
| Sight Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$3,450
- CLARUS$3,040
- Slit Lamps$2,941
- Tecnis Simplicity$2,450
- IOLMaster 700$1,380
- IFS ADVANCED FEMTOSEC LASER$1,300
- INTRALASE FS FEMTOSEC LASER$1,300
- VisuMax$1,170
- MEL 90$1,170
- CIRRUS HD-OCT$1,170
- CALLISTO eye$1,170
- LENSAR LASER SYSTEM$671
- Ahmed Glaucoma Valve$500
- Kahook Dual Blade$500
- Humphrey HFA$253
- IOLMaster$228
- QUATERA 700$210
- Clareon$179
- RXSIGHT CONTACT LENS$163
- RXSIGHT INJECTOR CARTRIDGE$163
How this compares
$22,545 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 19 | $14,048 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 82 | $5,165 |
| Fluorometholone | 57 | $4,494 |
| Loteprednol Etabonate | 20 | $3,102 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,866 |
| Prednisolone Acetate | 53 | $2,759 |
| Ketorolac Tromethamine | 92 | $2,611 |
| Difluprednate | 11 | $1,224 |
| Timolol Maleate | 24 | $328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $670 | $14,04819 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $102 | $5,96831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Chippewa Falls
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
- Julia AgapovMadison$26K
- Michael VrabecAppleton$20K
- Philip SmithMinocqua$18K
- Syed Shahla Crosse$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.